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Background/aim: Hypercholesterolemia is characterized by changes in lipid profile, nitric oxide pathway, and oxidative stress markers,
but functions of high-density lipoprotein (HDL) were not well established in hypercholesterolemic subjects treated with atorvastatin.
In this study, we aimed to evaluate effects of atorvastatin treatment on functionality of HDL, oxidative stress, and endothelial functions
in hypercholesterolemic subjects.
Materials and methods: Thirty patients (20 females, 10 males) aged from 40 to 60 years and diagnosed as hypercholesterolemic
were included. Patients were treated with 10 mg/day atorvastatin for 3 months. Markers of endothelial functions, namely asymmetric
dimethylarginine (ADMA), homocysteine, and nitric oxide (NO), and markers of oxidative status, namely malondialdehyde (MDA),
antioxidant potential (AOP), paraoxonase 1 (PON1), and arylesterase, were measured. Before and after atorvastatin treatment, glucose,
lipid parameters, and antioxidant/antiinflammatory HDL levels were also measured.
Results: ADMA and homocysteine levels were decreased whereas NO levels were increased with atorvastatin therapy. MDA levels were
decreased but AOP, PON1, and arylesterase levels and antiinflammatory characteristics of HDLs were increased. Furthermore, lipid
profiles of the patients improved with atorvastatin therapy.
Conclusion: Hypercholesterolemia is a cause of oxidative stress, endothelial dysfunction, and proinflammatory HDL levels. Atorvastatin
is a beneficial pharmacological modulator of impaired antiinflammatory HDL-C levels, endothelial functions, and oxidative status
against atherosclerosis indicating pleiotropic effects of statins.
Key words: Antioxidant/antiinflammatory high-density lipoprotein, atorvastatin, hypercholesterolemia, oxidative stress

1. Introduction
Hypercholesterolemia is one of the established risk factors
in the pathogenesis of atherosclerosis and subsequent
coronary heart disease (1). Endothelial function is impaired
by the decrease in synthesis and release of endotheliumderived relaxing factors or by the inactivation after reaction
with superoxide radicals (2–4). Nitric oxide (NO), which
is a potent endogenous vasodilator, is generated by NO
synthase (NOS) in the endothelium. Decreased NO
production impairs endothelium-dependent vasodilation
and also accelerates the development of vascular events (5).
Asymmetric dimethylarginine (ADMA) is an
endogenous competitive inhibitor of NOS and a marker
for atherosclerosis in circulation; it may be a novel risk
factor for endothelial dysfunction and coronary artery
diseases. It is synthesized with N-methyl transferases from
proteins (5,6).
* Correspondence: gakalin@anadolu.edu.tr

Elevated levels of homocysteine are an independent
risk factor for cardiovascular diseases. Homocysteine
may contribute to enhanced oxidative inactivation of NO
by its redox activity, which arises from the formation of
disulfides and the generation of hydrogen peroxide and
superoxide anion (7). Increased levels of homocysteine
have been shown to inhibit the activity of dimethylarginine
dimethylaminohydrolase, which is responsible for the
metabolism of ADMA (7) and causes an accumulation of
ADMA (5). Deterioration in the homocysteine metabolism
may also induce oxidative stress. Homocysteine increases
expression of TNF-α, which increases oxidative stress.
S-adenosylmethionine, an intermediate in homocysteine
metabolism, is a source of methyl groups that are involved
in ADMA (5).
Paraoxonase 1 (PON1), which catalyzes the hydrolysis
of biologically active lipids in oxidized low-density
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lipoprotein (8), is one such protein that has been reported to
possess both antioxidant and antiinflammatory properties
(8). Homocysteine thiolactone, which is a both toxic and
cytotoxic metabolic product of homocysteine, is detoxified
by the homocysteine thiolactonase activity of PON1 (7).
Hence, PON1 prevents protein homocysteinylation, the
process involved in atherogenesis.
Statins,
3-hydroxy-3-methylglutaryl
coenzyme
A reductase inhibitors, are widely used for
hypercholesterolemia treatment and have cardioprotective
and antioxidant effects regardless of their lipid lowering
effects. Some statins and their metabolites also act as
free radical scavengers, reducing reactive oxygen species
(ROS) formation (7). Statins increase serum PON1
activity, improve endothelial function, enhance the
stability of atherosclerotic plaques, and suppress vascular
inflammation (9).
The aim of our study was to examine the shortterm protective effect of statins on endothelial
dysfunction and atherosclerosis processes in patients
with hypercholesterolemia. For evaluating endothelial
dysfunction, ADMA, NO, and homocysteine levels;
oxidant/antioxidant status; and lipid profile, especially
the functionality of high-density lipoprotein (HDL), were
determined.
2. Materials and methods
Thirty patients (20 females, 10 males) with
hypercholesterolemia aged from 40 to 60 years and
admitted to the Endocrinology Department of the
Eskişehir Osmangazi University Medical School were
included in the study. The study inclusion criteria for
patients were to carry two or more risk factors for
coronary heart disease (hypertension, smoking, diabetes,
physical inactivity, unhealthy diet, obesity, elevated blood
cholesterol, excessive stress) and low-density lipoprotein
cholesterol (LDL-C) levels in the range of 130–300 mg/dL,
or to carry one or no risk factor for coronary heart diseases
and LDL-C levels in the range of 160–300 mg/dL.
Before and 3 months after the statin treatment after
12 h of overnight fasting, blood samples were collected
from each patient in both heparinized and polymer gel
containing tubes to obtain serum and plasma, respectively.
Thirty patients were orally administered atorvastatin (10
mg/day) for 3 months. Other lipid-lowering drugs and
over-the-counter agents such as niacin or omega-3 were
not allowed. Blood samples were collected in the same
manner. A control group consisted of 30 healthy subjects
who were not on any medication and did not smoke.
Patients with established atherosclerotic vascular disease
or diabetes and patients with lipid disorders other than
hypercholesterolemia were not included in the study.
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Markers of endothelial functions, namely ADMA,
homocysteine, and NO, and markers of oxidative status,
namely malondialdehyde (MDA), antioxidant potential
(AOP), PON1, and arylesterase, were measured. Before
and after atorvastatin treatment, lipid parameters and
antioxidant/antiinflammatory HDL levels were also
measured.
Blood samples were centrifuged at 1097 × g for 10 min
(Jouan MR 22). Serum, total cholesterol (TC), LDL-C,
high-density lipoprotein cholesterol (HDL-C), triglyceride
(TG), apolipoprotein (Apo A1), and apolipoprotein
(Apo B) were immediately measured with Roche
Diagnostic kits in a Modular Systems (Roche Diagnostics)
analyzer according to the manufacturer’s instructions.
Lipoprotein(a) (Lp(a)), Apo A1, and Apo B levels were
measured by immunoturbidimetric method with Roche
Diagnostic kits in a Modular Systems (Roche Diagnostics)
analyzer according to the manufacturer’s instructions.
Part of the serum and plasma samples were frozen at –80
°C (Jouan VX350 series, Thermo Electron) without delay
until the analysis of other parameters.
Nitrate and nitrite, which reflect the best index of total
NO production, are the final and stable end products of
NO in vivo. Nitrate was assayed by a slight modification
of the cadmium-reduction method, as defined by Cortas
and Wakid, and absorbance was read against the blank at
540 nm after 30 min (10). ADMA levels were measured
according to the Jones and Wu method with minor
modifications and results were given as µmol/L (11,12).
Homocysteine and MDA levels were measured with a
Chromsystems Diagnostic commercial kit (Munich,
Germany) using an Agilent HP 1100-Model HPLC system
equipped with an autosampler and a fluorescence detector.
Serum AOP was measured by a method described by
Durak et al. (13). AOP values were assessed from the
difference between MDA levels of control and sample
studies and expressed as U/h. PON1 activity was measured
with a fully automated paraoxonase activity measurement
kit (Rel Assay Diagnostics) in a Modular P (Roche
Diagnostics) analyzer according to the manufacturer’s
instructions. The enzyme activity was expressed in U/L.
Arylesterase activity was measured with a fully automated
arylesterase measurement kit (Rel Assay Diagnostics) in
a Modular P (Roche Diagnostics) analyzer according to
the manufacturer’s guidelines. The enzyme activity was
expressed in U/L. Antiinflammatory properties of HDL
were determined by the change in fluorescence intensity
resulting from oxidation of DCFH by LDL in the presence
of tested HDL (14). HDL isolation from subject samples
was carried out by dextran sulfate precipitation method
(14).
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2.1. Statistical analysis
SPSS 13.0 for Windows was used for statistical analysis.
Data are expressed as mean ± SD. Comparisons were
performed by one-way ANOVA (Tukey post hoc analyses)
for normally distributed continuous variables or Kruskal–
Wallis H test for nonnormally distributed variables for
several independent samples.
2.2. Ethics statement
All subjects were informed about the study protocol
and written consent was obtained. Institutional ethics
committee approval was received before the beginning of
the study (30.06.09/40).
3. Results
In our study, hypercholesterolemic patients’ lipid profile
parameters, except HDL-C and Apo A1, were significantly
increased. HDL-C and Apo A1 levels were significantly
decreased when compared with controls (Table 1).

After atorvastatin treatment, TC, LDL-C, and Apo
B levels (P < 0.001) and Apo (a) levels (P < 0.05) were
significantly decreased (Table 1).
In our study, before treatment the group’s ADMA,
homocysteine, and MDA levels were significantly
increased (P < 0.001), whereas NO, AOP, PON1, and
arylesterase levels were significantly decreased compared
to controls (P < 0.001) (Table 2).
On the other hand, after atorvastatin treatment,
ADMA, homocysteine, and MDA levels were significantly
decreased compared to hypercholesterolemic values (P <
0.001). NO (P < 0.001), PON1 (P < 0.001), and arylesterase
(P < 0.01) levels were significantly increased compared to
hypercholesterolemics. After treatment AOP levels were
increased compared to hypercholesterolemic values, but
this was not statistically significant (P > 0.05) (Table 2).
Antiinflammatory properties of HDL against LDL
oxidation was measured by dichlorofluorescin assay.

Table 1. Lipid profiles of hypercholesterolemic patients before and after treatment (mean ± SD).
Parameters

Control

Triglyceride (mg/dL)

Hypercholesterolemic patients
Before treatment

After treatment

118.5 ± 60.6

173.0 ± 62.1

148.2 ± 60.3*

Total Cholesterol (mg/dL)

196.4 ± 40.6

257.3 ± 52.4***

201.9 ± 34.9###

HDL-C (mg/dL)

52.4 ± 7.8

47.5 ± 10.8*

52.3 ± 9.3

LDL-C (mg/dL)

122.4 ± 30.3

171.6 ± 42.3

130.9 ± 30.6###

Lp(a) (mg/dL)

39.5 ± 19.5

60.0 ± 25.5***

46.4 ± 12.4*,#

Apo (A1) (mg/dL)

162.2 ± 11.9

152.4 ± 22.7*

160.1 ± 18.6

Apo (B) (mg/dL)

84.8 ± 23.7

135.9 ± 17.8**

98.3 ± 25.2*, ###

*

*

*P < 0.05 vs. control, **P < 0.01 vs. control, ***P < 0.001 vs. control, #P < 0.05 vs. study group before treatment, ###P < 0.001 vs. study
group before treatment.
Table 2. The oxidative status and endothelial function parameters of hypercholesterolemic patients before and after treatment (mean ± SD).
Parameters

Control

ADMA (µmol/L)

Hypercholesterolemic patients
Before treatment

After treatment

0.41 ± 0.08

0.73 ± 0.18

0.57 ± 0.12###

Homocysteine (µmol/L)

10.91 ± 2.8

14.8 ± 3.12***

12.4 ± 2.7###

NO (µmol/L)

20.8 ± 17.6

9.8 ± 9.2***

16.2 ± 3.6***,###

MDA (nmol/L)

0.05 ± 0.03

0.09 ± 0.02***

0.06 ± 0.03###

AOP (U/h)

10.08 ± 1.4

6.49 ± 3.9***

9.19 ± 2.8*

PON1 (U/L)

176.5 ± 31.3

126.8 ± 32.5***

164.3 ± 33.9*,###

Arylesterase (U/L)

439.5 ± 79.6

342.9 ± 66.5***

382.4 ± 80.2**,#

***

*P < 0.05 vs. control, **P < 0.01 vs. control, ***P < 0.001 vs. control, #P < 0.05 vs. study group before treatment, ###P < 0.001 vs. study
group before treatment.
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Hypercholesterolemia caused a significant decrease in
antiinflammatory capacity of HDL compared to the control
group (P < 0.001). Atorvastatin treatment increased HDL
antiinflammatory capacities in hypercholesterolemic
patients (P < 0.01) (Table 3).

al. showed that antioxidant effects of statins were attributed
to their reducing the generation of ROS by inhibition
of vascular NAD(P)H oxidase, modification of redox
homeostasis in LDL particles, inhibition of the respiratory
burst of phagocytes, modulation of the RNA expression,
antagonization of the prooxidant effect of angiotensin II
and endothelin-1, increase of the upregulation of eNOS
expression/activity and vascular NO, and binding to
surface phospholipid of lipoproteins (7). Sathyapalan et
al. showed that atorvastatin reduced MDA concentrations
in patients with polycystic ovary syndrome, indicating
pleotropic effects of atorvastatin, as in our study (18).
Its known that statins increase triglyceride-rich
lipoprotein catabolism and decrease LDL-C levels (19).
In our study, LDL-C and Apo B levels were significantly
decreased, as indicated in the Atorvastatin Comparative
Cholesterol Efficacy and Safety Study after 3 months of
statin therapy (20). HDL-C and Apo A1 levels did not
change because statins have fewer effects on Apo A1 in
patients with hypercholesterolemia (20). In some studies
it was shown that statin treatment increased Lp(a) levels
(21,22), but in some studies controversial effects were
reported, as in ours (23,24). Maron et al. showed that statin
treatment did not affect Lp(a) levels (25). These results
may be explained by individual mutational differences, as
indicated by Bolewski et al. (26).
PON1 is an antioxidant enzyme that circulates in the
blood in HDL particles and has arylesterase and lactonase
activities. It protects against lipid peroxidation by its ability
to hydrolyze lipids and degrade H2O2 (7). HDL is likely to
be an important determinant of PON1 activity, which is
responsible for antioxidant and antiinflammatory capacity.
In support of this, we observed a direct relationship
between mean HDL-cholesterol levels and PON1 levels in
controls and hypercholesterolemics (8).
In this study, prooxidant/proinflammatory HDL,
MDA, and AOP results show the presence of oxidative
stress. Decreases in PON1 activities before treatment
may depend on these oxidative stresses. Previous
studies (7,8) suggested that oxidative stress depresses
PON1 activity with inadequate antioxidant capacity,

4. Discussion
In the present study we demonstrated that 3 months of
atorvastatin treatment markedly decreased oxidative
stress and prooxidant/proinflammatory HDL levels and
improved endothelial dysfunctions in the studied patients.
Over the last decades, emerging data have suggested
that HDL functionality is more important than its
quantity (15). Thus, studies have focused on investigating
modulation of nonfunctional/proatherogenic HDL by
pharmaceutical drugs. In particular, lipid-lowering drugs
such as statins are mostly used for hypercholesterolemia
(16). Thus, we studied the preventive role of atorvastatin
on hypercholesterolemic patients against oxidative stress,
endothelial dysfunction, and prooxidant/proinflammatory
HDL functions.
Oxidative stress in the endothelium is known
to contribute to the atherogenesis process. During
atherogenesis, lipid peroxidation takes place in arterial
macrophages and lipoproteins, which are rich in
polyunsaturated fatty acid (7). Measurement of breakdown
products such as MDA is the most common approach to
determine the degree of lipid peroxidation induced by
ROS (17). In this study, hypercholesterolemia increased
MDA levels and decreased AOP levels compared to
controls, indicating the presence of increased oxidative
stress in hypercholesterolemia (P < 0.001). Since
AOP reflects the total capacity of the enzymatic and
nonenzymatic antioxidant defense system, a decrease in
AOP demonstrates impairment in the total antioxidant
defense system in hypercholesterolemia (17).
On the other hand, atorvastatin treatment decreased
MDA levels (P < 0.001). The decreases in lipid peroxide
levels may arise from decreased LDL-C levels by treatment
with atorvastatin, since this drug may cause removal of
‘aged LDL’, which is more prone to oxidation. Bolayirli et

Table 3. HDL score and percentage of pro- and antiinflammatory HDLs in groups.
>1

<1

% Proinflammatory HDL

% Antiinflammatory HDL

4.87 ± 0.99

6.7

93.3

Before treatment

8.86 ± 3.49

66.7

33.3

After treatment

6.10 ± 2.61*, ##

23.3

76.6

Groups

HDL score (FU)

Control

***

									
*P < 0.05 vs. control, ***P < 0.001 vs. control, ##P < 0.01 vs. before treatment group.
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excess oxidative stress, and inflammatory response, as
evident in hypercholesterolemic patients. Furthermore,
hypercholesterolemia is known to reduce PON1 activity
through the interactions between the free sulfhydryl
group of enzyme and oxidized lipids. In line with
our findings, Hong et al. showed decreases in serum
PON1 concentrations in high-cholesterol diet-induced
hypercholesterolemia in rabbits (27). In our study, before
and after atorvastatin treatment, the study group’s PON1
levels were increased, indicating that atorvastatin as used in
this study had antioxidant effects on hypercholesterolemia.
PON1 activity was increased inversely proportionally to
decreased lipid peroxides caused by ROS. It was shown that
atorvastatin increased PON1 activities in different clinical
and experimental studies, in line with our study (28–32),
whereas some others failed to find any changes in serum
paraoxonase activity following simvastatin or atorvastatin
administration (16). Deakin et al. (33) explained that
patients with the –108C allele, who already have higher
PON1 levels, may further benefit from treatment with
statins, indicating the importance of gene polymorphism
among individuals.
The decreased activity of PON1 can depress the ability
of circulating HDL particles to protect LDL from oxidation,
to participate in the reverse cholesterol transport pathway,
and to inhibit monocyte–endothelial cell interaction.
All of these appear to be important in the inflammatory
response in arteries that promotes atherogenesis. Beside
this low PON1 activity, the tyrosine residues in Apo
A1 may be modified by myeloperoxidase, which is a
determinant of inflammatory state. Thus, Apo A1 levels
and functions may decrease as a result of nonfunctional
proinflammatory HDL against LDL oxidation and
inability of HDL to promote cholesterol efflux by the
ATP-binding cassette transporter A-1 pathway (34). All
these events cause increasing proinflammatory HDL,
which has proatherogenic characteristics as seen in our
hypercholesterolemic patients (8). Decrease in Apo A1
levels may partly explain the nonfunctional HDL. On the
other hand, statins may activate PPAR-γ receptors (33).

It was also reported that PPAR-γ activation affects ATPbinding cassette transporter A-1 expression, which is
pivotal for HDL biogenesis (35).
In our study, atorvastatin treatment increased HDL’s
antioxidant/antiinflammatory capacity (P < 0.01), whereas
it did not change HDL-C levels in hypercholesterolemics,
indicating that this drug has an effect not only on PON1
activities but also on particle size, surface phospholipids,
other antiinflammatory and antioxidant particles, and
apoproteins, which are most important to hold and
stabilize PON1 in HDL (8). It was reported that LCAT,
ATP-binding cassette transporter, and platelet-activating
factor acetylhydrolase have beneficial effects on HDL’s
protective effects against LDL oxidation beside its PON1
activity (15,36).
Increased homocysteine and ADMA and decreased
NO levels are markers of endothelial dysfunctions as seen
in our hypercholesterolemics. On the contrary, treatment
with atorvastatin improved endothelial functions of
these patients. Studies to date indicated that statins have
no or little effect on ADMA and homocysteine levels, in
contrast to our study (6,7). Our study group included
different numbers of females (n = 20) and males (n = 10).
The increased ADMA levels may thus be explained by
beneficial effects of estrogen on the endothelium.
In conclusion, hypercholesterolemia is a cause
of oxidative stress and endothelial dysfunction and
prooxidant/proinflammatory HDL levels. Our results
documented significant improvement in oxidative stress
parameters and HDL’s antiinflammatory capacity in
hypercholesterolemic patients after atorvastatin treatment.
Hence, this study shows that atorvastatin therapy is a
beneficial strategy for improvement of HDL’s antioxidant/
antiinflammatory capacity and endothelial dysfunction
against atherosclerosis.
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